Pre-Treatment Neutrophil Count as a Predictor of Antituberculosis Therapy Outcomes: A Multicenter Prospective Cohort Study

Detalhes bibliográficos
Autor(a) principal: Carvalho, Anna Cristina C.
Data de Publicação: 2021
Outros Autores: Amorim, Gustavo, Melo, Mayla G. M., Silveira, Ana Karla A., Vargas, Pedro H. L., Moreira, Adriana S. R., Rocha, Michael Santos, Souza, Alexandra B., Arriaga Gutiérrez, María Belen, Pereira, Mariana Araújo, Figueiredo, Marina C., Durovni, Betina, Silva, José R. Lapa e, Cavalcante, Solange, Rolla, Valeria C., Sterling, Timothy R., Santos, Marcelo Cordeiro, Andrade, Bruno de Bezerril, Silva, Elisangela C., Kritski, Afrânio L., RePORT Brazil consortium
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da FIOCRUZ (ARCA)
Texto Completo: https://www.arca.fiocruz.br/handle/icict/48291
Resumo: 1 Laboratório de Inovações em Terapias, Ensino e Bioprodutos (LITEB), Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil, 2 Programa Acadeˆ mico de Tuberculose da Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, 3 Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, United States, 4 Laboratório de Micobacteriologia Molecular, Faculdade de Medicina e Complexo Hospitalar Hospital Universita´ rio Clementino Fraga Filho—Instituto de Doenças do Tórax da Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, 5 Multinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative, Salvador, Brazil, 6 Instituto Brasileiro para Investigação da Tuberculose, Fundação Jose´ Silveira, Salvador, Brazil, 7 Gerência de Micobacteriologia, Fundação de Medicina Tropical Doutor Heitor Vieira Dourado, Manaus, Brazil, 8 Laborato´ rio de Inflamac¸ão e Biomarcadores, Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Brazil, 9 Faculdade de Medicina, Universidade Federal da Bahia, Salvador, Brazil, 10 Division of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, United States, 11 Secretaria Municipal de Sau´ de do Rio de Janeiro, Rio de Janeiro, Brazil, 12 Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil, 13 Curso de Medicina, Escola Bahiana de Medicina e Saú de Pública, Salvador, Brazil, 14 Curso de Medicina, Universidade Salvador (UNIFACS), Salvador, Brazil, 15 Laborato´ rio Reconhecer Biologia, Centro de Biociência e Biotecniologia, Universidade Estadual do Norte Fluminense Darcy Ribeiro, Rio de Janeiro, Brazil
id CRUZ_3704b3a18e037ac9e4d7787fff13dc12
oai_identifier_str oai:www.arca.fiocruz.br:icict/48291
network_acronym_str CRUZ
network_name_str Repositório Institucional da FIOCRUZ (ARCA)
repository_id_str 2135
spelling Carvalho, Anna Cristina C.Amorim, GustavoMelo, Mayla G. M.Silveira, Ana Karla A.Vargas, Pedro H. L.Moreira, Adriana S. R.Rocha, Michael SantosSouza, Alexandra B.Arriaga Gutiérrez, María BelenPereira, Mariana AraújoFigueiredo, Marina C.Durovni, BetinaSilva, José R. Lapa eCavalcante, SolangeRolla, Valeria C.Sterling, Timothy R.Santos, Marcelo CordeiroAndrade, Bruno de BezerrilSilva, Elisangela C.Kritski, Afrânio L.RePORT Brazil consortium2021-07-20T11:21:30Z2021-07-20T11:21:30Z2021CARVALHO, Anna Cristina C. et al. Pre-Treatment Neutrophil Count as a Predictor of Antituberculosis Therapy Outcomes: A Multicenter Prospective Cohort Study. Frontiers in Immunology, 2021.1664-3224https://www.arca.fiocruz.br/handle/icict/4829110.3389/fimmu.2021.6619341 Laboratório de Inovações em Terapias, Ensino e Bioprodutos (LITEB), Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil, 2 Programa Acadeˆ mico de Tuberculose da Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, 3 Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, United States, 4 Laboratório de Micobacteriologia Molecular, Faculdade de Medicina e Complexo Hospitalar Hospital Universita´ rio Clementino Fraga Filho—Instituto de Doenças do Tórax da Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, 5 Multinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative, Salvador, Brazil, 6 Instituto Brasileiro para Investigação da Tuberculose, Fundação Jose´ Silveira, Salvador, Brazil, 7 Gerência de Micobacteriologia, Fundação de Medicina Tropical Doutor Heitor Vieira Dourado, Manaus, Brazil, 8 Laborato´ rio de Inflamac¸ão e Biomarcadores, Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Brazil, 9 Faculdade de Medicina, Universidade Federal da Bahia, Salvador, Brazil, 10 Division of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, United States, 11 Secretaria Municipal de Sau´ de do Rio de Janeiro, Rio de Janeiro, Brazil, 12 Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil, 13 Curso de Medicina, Escola Bahiana de Medicina e Saú de Pública, Salvador, Brazil, 14 Curso de Medicina, Universidade Salvador (UNIFACS), Salvador, Brazil, 15 Laborato´ rio Reconhecer Biologia, Centro de Biociência e Biotecniologia, Universidade Estadual do Norte Fluminense Darcy Ribeiro, Rio de Janeiro, BrazilDepartamento de Ciência e Tecnologia, Ministério da Saúde, Brazil and the National Institutes of Allergy and Infectious Diseases, USA. The work of AK, BA, ES, GA, AC, MF, JL, SC, VR, BD, TS, and MC-S was supported by grants from NIH (U01AI069923, R01AI120790). BA, AK, and JL are senior scientists from the Conselho Nacional de Desenvolvimento Cientı́fico e Tecnológico (CNPq). MM received a scholarship from CNPq. MA received a scholarship from Fundação de Amparo à Pesquisa do Estado da Bahia (FAPESB). MA-P received a research fellowship from the Coordenação de Aperfeiçoamento de Pessoal de Nı́vel Superior (CAPES, finance code: 001). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."Múltipla ver em Notas"Neutrophils have been associated with lung tissue damage in many diseases, including tuberculosis (TB). Whether neutrophil count can serve as a predictor of adverse treatment outcomes is unknown. Methods: We prospectively assessed 936 patients (172 HIV-seropositive) with cultureconfirmed pulmonary TB, enrolled in a multicenter prospective cohort study from different regions in Brazil, from June 2015 to June 2019, and were followed up to two years. TB patients had a baseline visit before treatment (month 0) and visits at month 2 and 6 (or at the end of TB treatment). Smear microscopy, and culture for Mycobacterium tuberculosis (MTB) were performed at TB diagnosis and during follow-up. Complete blood counts were measured at baseline. Treatment outcome was defined as either unfavorable (death, treatment failure or TB recurrence) or favorable (cure or treatment completion). We performed multivariable logistic regression, with propensity score regression adjustment, to estimate the association between neutrophil count with MTB culture result at month 2 and unfavorable treatment outcome. We used a propensity score adjustment instead of a fully adjusted regression model due to the relatively low number of outcomes. Results: Among 682 patients who had MTB culture results at month 2, 40 (5.9%) had a positive result. After regression with propensity score adjustment, no significant association between baseline neutrophil count (103/mm3) and positive MTB culture at month 2 was found among either HIV-seronegative (OR = 1.06, 95% CI = [0.95;1.19] or HIV-seropositive patients (OR = 0.77, 95% CI = [0.51; 1.20]). Of 691 TB patients followed up for at least 18 months and up to 24 months, 635 (91.9%) were either cured or completed treatment, and 56 (8.1%) had an unfavorable treatment outcome. A multivariable regression with propensity score adjustment found an association between higher neutrophil count (103/mm3) at baseline and unfavorable outcome among HIV-seronegative patients [OR= 1.17 (95% CI= [1.06;1.30]). In addition, adjusted Cox regression found that higher baseline neutrophil count (103/mm3) was associated with unfavorable treatment outcomes overall and among HIV-seronegative patients (HR= 1.16 (95% CI = [1.05;1.27]). Conclusion: Increased neutrophil count prior to anti-TB treatment initiation was associated with unfavorable treatment outcomes, particularly among HIV-seronegative patients. Further prospective studies evaluating neutrophil count in response to drug treatment and association with TB treatment outcomes are warranted.engFrontiers MediaTuberculoseNeutrófilosTratamentoBiomarcadoresContagem de neutrófilosTuberculosisNeutrophilsTreatment outcomeBiomarkersNeutrophil countPre-Treatment Neutrophil Count as a Predictor of Antituberculosis Therapy Outcomes: A Multicenter Prospective Cohort Studyinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-83097https://www.arca.fiocruz.br/bitstream/icict/48291/1/license.txt36b51ef91c52b5338d9d29ba0cc807bcMD51ORIGINALCarvalho, Anna Cristina C Pre-treatment....pdfCarvalho, Anna Cristina C Pre-treatment....pdfapplication/pdf982087https://www.arca.fiocruz.br/bitstream/icict/48291/2/Carvalho%2c%20Anna%20Cristina%20C%20Pre-treatment....pdf800d01dcb2d963da9bcb23059b8678efMD52TEXTCarvalho, Anna Cristina C Pre-treatment....pdf.txtCarvalho, Anna Cristina C Pre-treatment....pdf.txtExtracted texttext/plain56074https://www.arca.fiocruz.br/bitstream/icict/48291/3/Carvalho%2c%20Anna%20Cristina%20C%20Pre-treatment....pdf.txt133133ca6bc7710c0bee99f11ef27bafMD53icict/482912023-03-15 14:34:13.922oai:www.arca.fiocruz.br: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Repositório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352023-03-15T17:34:13Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.pt_BR.fl_str_mv Pre-Treatment Neutrophil Count as a Predictor of Antituberculosis Therapy Outcomes: A Multicenter Prospective Cohort Study
title Pre-Treatment Neutrophil Count as a Predictor of Antituberculosis Therapy Outcomes: A Multicenter Prospective Cohort Study
spellingShingle Pre-Treatment Neutrophil Count as a Predictor of Antituberculosis Therapy Outcomes: A Multicenter Prospective Cohort Study
Carvalho, Anna Cristina C.
Tuberculose
Neutrófilos
Tratamento
Biomarcadores
Contagem de neutrófilos
Tuberculosis
Neutrophils
Treatment outcome
Biomarkers
Neutrophil count
title_short Pre-Treatment Neutrophil Count as a Predictor of Antituberculosis Therapy Outcomes: A Multicenter Prospective Cohort Study
title_full Pre-Treatment Neutrophil Count as a Predictor of Antituberculosis Therapy Outcomes: A Multicenter Prospective Cohort Study
title_fullStr Pre-Treatment Neutrophil Count as a Predictor of Antituberculosis Therapy Outcomes: A Multicenter Prospective Cohort Study
title_full_unstemmed Pre-Treatment Neutrophil Count as a Predictor of Antituberculosis Therapy Outcomes: A Multicenter Prospective Cohort Study
title_sort Pre-Treatment Neutrophil Count as a Predictor of Antituberculosis Therapy Outcomes: A Multicenter Prospective Cohort Study
author Carvalho, Anna Cristina C.
author_facet Carvalho, Anna Cristina C.
Amorim, Gustavo
Melo, Mayla G. M.
Silveira, Ana Karla A.
Vargas, Pedro H. L.
Moreira, Adriana S. R.
Rocha, Michael Santos
Souza, Alexandra B.
Arriaga Gutiérrez, María Belen
Pereira, Mariana Araújo
Figueiredo, Marina C.
Durovni, Betina
Silva, José R. Lapa e
Cavalcante, Solange
Rolla, Valeria C.
Sterling, Timothy R.
Santos, Marcelo Cordeiro
Andrade, Bruno de Bezerril
Silva, Elisangela C.
Kritski, Afrânio L.
RePORT Brazil consortium
author_role author
author2 Amorim, Gustavo
Melo, Mayla G. M.
Silveira, Ana Karla A.
Vargas, Pedro H. L.
Moreira, Adriana S. R.
Rocha, Michael Santos
Souza, Alexandra B.
Arriaga Gutiérrez, María Belen
Pereira, Mariana Araújo
Figueiredo, Marina C.
Durovni, Betina
Silva, José R. Lapa e
Cavalcante, Solange
Rolla, Valeria C.
Sterling, Timothy R.
Santos, Marcelo Cordeiro
Andrade, Bruno de Bezerril
Silva, Elisangela C.
Kritski, Afrânio L.
RePORT Brazil consortium
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Carvalho, Anna Cristina C.
Amorim, Gustavo
Melo, Mayla G. M.
Silveira, Ana Karla A.
Vargas, Pedro H. L.
Moreira, Adriana S. R.
Rocha, Michael Santos
Souza, Alexandra B.
Arriaga Gutiérrez, María Belen
Pereira, Mariana Araújo
Figueiredo, Marina C.
Durovni, Betina
Silva, José R. Lapa e
Cavalcante, Solange
Rolla, Valeria C.
Sterling, Timothy R.
Santos, Marcelo Cordeiro
Andrade, Bruno de Bezerril
Silva, Elisangela C.
Kritski, Afrânio L.
RePORT Brazil consortium
dc.subject.other.pt_BR.fl_str_mv Tuberculose
Neutrófilos
Tratamento
Biomarcadores
Contagem de neutrófilos
topic Tuberculose
Neutrófilos
Tratamento
Biomarcadores
Contagem de neutrófilos
Tuberculosis
Neutrophils
Treatment outcome
Biomarkers
Neutrophil count
dc.subject.en.pt_BR.fl_str_mv Tuberculosis
Neutrophils
Treatment outcome
Biomarkers
Neutrophil count
description 1 Laboratório de Inovações em Terapias, Ensino e Bioprodutos (LITEB), Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil, 2 Programa Acadeˆ mico de Tuberculose da Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, 3 Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, United States, 4 Laboratório de Micobacteriologia Molecular, Faculdade de Medicina e Complexo Hospitalar Hospital Universita´ rio Clementino Fraga Filho—Instituto de Doenças do Tórax da Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, 5 Multinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative, Salvador, Brazil, 6 Instituto Brasileiro para Investigação da Tuberculose, Fundação Jose´ Silveira, Salvador, Brazil, 7 Gerência de Micobacteriologia, Fundação de Medicina Tropical Doutor Heitor Vieira Dourado, Manaus, Brazil, 8 Laborato´ rio de Inflamac¸ão e Biomarcadores, Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Brazil, 9 Faculdade de Medicina, Universidade Federal da Bahia, Salvador, Brazil, 10 Division of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, United States, 11 Secretaria Municipal de Sau´ de do Rio de Janeiro, Rio de Janeiro, Brazil, 12 Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil, 13 Curso de Medicina, Escola Bahiana de Medicina e Saú de Pública, Salvador, Brazil, 14 Curso de Medicina, Universidade Salvador (UNIFACS), Salvador, Brazil, 15 Laborato´ rio Reconhecer Biologia, Centro de Biociência e Biotecniologia, Universidade Estadual do Norte Fluminense Darcy Ribeiro, Rio de Janeiro, Brazil
publishDate 2021
dc.date.accessioned.fl_str_mv 2021-07-20T11:21:30Z
dc.date.available.fl_str_mv 2021-07-20T11:21:30Z
dc.date.issued.fl_str_mv 2021
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv CARVALHO, Anna Cristina C. et al. Pre-Treatment Neutrophil Count as a Predictor of Antituberculosis Therapy Outcomes: A Multicenter Prospective Cohort Study. Frontiers in Immunology, 2021.
dc.identifier.uri.fl_str_mv https://www.arca.fiocruz.br/handle/icict/48291
dc.identifier.issn.pt_BR.fl_str_mv 1664-3224
dc.identifier.doi.none.fl_str_mv 10.3389/fimmu.2021.661934
identifier_str_mv CARVALHO, Anna Cristina C. et al. Pre-Treatment Neutrophil Count as a Predictor of Antituberculosis Therapy Outcomes: A Multicenter Prospective Cohort Study. Frontiers in Immunology, 2021.
1664-3224
10.3389/fimmu.2021.661934
url https://www.arca.fiocruz.br/handle/icict/48291
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Frontiers Media
publisher.none.fl_str_mv Frontiers Media
dc.source.none.fl_str_mv reponame:Repositório Institucional da FIOCRUZ (ARCA)
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Repositório Institucional da FIOCRUZ (ARCA)
collection Repositório Institucional da FIOCRUZ (ARCA)
bitstream.url.fl_str_mv https://www.arca.fiocruz.br/bitstream/icict/48291/1/license.txt
https://www.arca.fiocruz.br/bitstream/icict/48291/2/Carvalho%2c%20Anna%20Cristina%20C%20Pre-treatment....pdf
https://www.arca.fiocruz.br/bitstream/icict/48291/3/Carvalho%2c%20Anna%20Cristina%20C%20Pre-treatment....pdf.txt
bitstream.checksum.fl_str_mv 36b51ef91c52b5338d9d29ba0cc807bc
800d01dcb2d963da9bcb23059b8678ef
133133ca6bc7710c0bee99f11ef27baf
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv repositorio.arca@fiocruz.br
_version_ 1813009223153352704